These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 9884874)

  • 41. Comparison of the pharmacodynamics of imipenem in patients with ventilator-associated pneumonia following administration by 2 or 0.5 h infusion.
    Jaruratanasirikul S; Sudsai T
    J Antimicrob Chemother; 2009 Mar; 63(3):560-3. PubMed ID: 19153079
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial.
    Basoli A; Meli EZ; Mazzocchi P; Speranza V
    Scand J Infect Dis; 1997; 29(5):503-8. PubMed ID: 9435041
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Myoclonus associated with intraperitoneal imipenem.
    Lau KK; Kink RJ; Jones DP
    Pediatr Nephrol; 2004 Jun; 19(6):700-1. PubMed ID: 15052466
    [No Abstract]   [Full Text] [Related]  

  • 44. A multicenter comparative study of meropenem and imipenem/cilastatin in the treatment of complicated urinary tract infections in hospitalized patients.
    Cox CE; Holloway WJ; Geckler RW
    Clin Infect Dis; 1995 Jul; 21(1):86-92. PubMed ID: 7578765
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use of regional administration of prophylactic antibiotics in total knee arthroplasty.
    Symonds T; Parkinson B; Hazratwala K; McEwen P; Wilkinson M; Grant A
    ANZ J Surg; 2018 Sep; 88(9):848-853. PubMed ID: 30151929
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Report of eight cases of pulmonary actinomycosis and their treatment with imipenem-cilastatin.
    Yew WW; Wong PC; Lee J; Fung SL; Wong CF; Chan CY
    Monaldi Arch Chest Dis; 1999 Apr; 54(2):126-9. PubMed ID: 10394825
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [A study on the penetration of imipenem/cilastatin sodium into the female genital tissues].
    Hongo M; Shimizu R; Sakae K; Kohchi T; Tada K; Tani M
    Jpn J Antibiot; 1986 May; 39(5):1389-400. PubMed ID: 3463785
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Imipenem combined with teicoplanin or vancomycin in the initial empirical treatment of febrile neutropenia. Analysis of the primary response and of a global sequential strategy in 126 episodes].
    Figuera A; Tomás JF; Hernández L; Jiménez ML; Peñarrubia MJ; del Rey MC; Arranz R; Cámara R; López-Lorenzo JL; Fernández-Rañada JM
    Rev Clin Esp; 1996 Aug; 196(8):515-22. PubMed ID: 8984537
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
    Ludwig E; Konkoly-Thege M; Kuti JL; Nicolau DP
    Int J Antimicrob Agents; 2006 Nov; 28(5):433-8. PubMed ID: 17046212
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. Meropenem Study Group.
    Geroulanos SJ
    J Antimicrob Chemother; 1995 Jul; 36 Suppl A():191-205. PubMed ID: 8543495
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Compatibility of imipenem-cilastatin sodium with commonly used intravenous solutions.
    Bigley FP; Forsyth RJ; Henley MW
    Am J Hosp Pharm; 1986 Nov; 43(11):2803-9. PubMed ID: 3467590
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients.
    Fournier A; Eggimann P; Pagani JL; Revelly JP; Decosterd LA; Marchetti O; Pannatier A; Voirol P; Que YA
    Burns; 2015 Aug; 41(5):956-68. PubMed ID: 25678084
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Fundamental and clinical studies of imipenem/cilastatin sodium in the field of obstetrics and gynecology].
    Naito H; Hara T; Akagi T; Masaoka T; Kudo Y; Iwasaki K; Matsuo M; Urabe T; Fujiwara A
    Jpn J Antibiot; 1986 May; 39(5):1401-11. PubMed ID: 3463786
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Is continuous infusion of imipenem always the best choice?
    Suchánková H; Lipš M; Urbánek K; Neely MN; Strojil J
    Int J Antimicrob Agents; 2017 Mar; 49(3):348-354. PubMed ID: 28189734
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Fundamental and clinical studies of imipenem/cilastatin sodium in the field of obstetrics and gynecology].
    Okamura K; Nakakuki M; Yamada K; Ikeno N; Watanabe M; Takahashi K; Muraguchi K; Saito A; Wakisaka T; Murai H
    Jpn J Antibiot; 1986 Jun; 39(6):1526-30. PubMed ID: 3463794
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Tolerance and safety of carbapenems: the use of meropenem].
    Lizasoaín M; Noriega AR
    Enferm Infecc Microbiol Clin; 1997 Sep; 15 Suppl 1():73-7. PubMed ID: 9410074
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Combination therapy of antibiotics and intravenous immunoglobulin].
    Masaoka T
    Nihon Rinsho; 2001 Apr; 59(4):781-4. PubMed ID: 11305006
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics of imipenem-cilastatin following intravenous administration in healthy adult horses.
    Orsini JA; Moate PJ; Boston RC; Norman T; Engiles J; Benson CE; Poppenga R
    J Vet Pharmacol Ther; 2005 Aug; 28(4):355-61. PubMed ID: 16050815
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Imipenem.
    Salaria M
    Indian Pediatr; 2001 Dec; 38(12):1370-3. PubMed ID: 11752734
    [No Abstract]   [Full Text] [Related]  

  • 60. [Clinical study on imipenem/cilastatin sodium in the field of pediatrics].
    Minamitani M; Hachimori K; Kaneda K
    Jpn J Antibiot; 1986 Jul; 39(7):1817-27. PubMed ID: 3464780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.